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Abstract 
Introduction 
Regulatory bodies such as the European Medicines Agency register medications (formulation, 
route of administration) for specific clinical indications. Once registered, prescription is at 
each clinician’s discretion. Off-label use is beyond the registered (licensed) uses.  Whilst off-
label prescribing is prevalent and, at times, may be clinically appropriate, in many cases 
detailed evaluation of the efficacy and toxicity is lacking.  
 
Methods 
A survey of palliative medicine clinicians examined understanding and practice of off-label 
prescribing, including unit policies regarding consent and commonly used off-label 
medication/indication dyads. These dyads were classified into unregistered, off- and on-
label, and whether medications were reimbursed. 
 
Results 
105 clinicians responded (53% response rate).  The majority did not have unit policies on 
off-label medications, and documented consent poorly.  236 medication/indication dyads 
were proposed, for 36 medications.  45 dyads (19%) for two medications were unregistered.  
118 dyads (50%) for 26 medications were off-label, and the remaining 73 dyads (31%) for 12 
medications were on-label. 
 
Conclusion 
Off-label prescribing with its clinical, legal and ethical implications is common yet poorly 
recognised by clinicians. For clinicians, the primary distinction required is understanding the 
difference between times where:  
- quality evidence exists but registration has not been updated by the pharmaceutical 
sponsors; and  
- the evidence has not been generated (or exists and suggests that there is no net benefit).  
Further research is required to determine the prevalence, clinical benefit and iatrogenic 
harm from off-label prescribing in palliative care, in order to determine clinical research 
priorities or to update registration.  
  
 
Keywords 
Off-label prescribing, drug regulation, physician knowledge, palliative care, iatrogenic harm 
Introduction 
In Australia, the Therapeutic Goods Administration (TGA) has a similar role to the European 
Medicines Agency (EMEA) in Europe and Food and Drug Administration (FDA) in the United States in 
registering medications (formulation, strength and route of administration) for specific indications 
(population and disease).  However once the medication has been approved, the clinician prescribes 
and may choose to use the medication in an off-label (unlicensed) manner – i.e. an unapproved 
dose, route of administration and/or indication.  This is distinct from an unregistered medication that 
is not approved by the regulatory authorities for any indication in their jurisdiction. 
 
Off-label prescribing occurs in three contexts in clinical practice:1 
1. When approval does not extend to cover the particular dose or indication, although 
evidence of efficacy is available - often because evidence became available after the 
medication was registered or after patent has expired, and the label has not been updated; 
2. In areas of medicine where high-level evidence is difficult to generate, even for treatments 
which are likely to be effective, or because there is a lack of a commercial imperative eg. 
rare diseases where adequately powered clinical trials are impossible, or new indications for 
medications are now out of patent.  In these situations there may be compelling biological 
plausibility and/or lower level evidence to support prescribing; or 
3. When the medication is proven to be ineffective or there is no reason to believe it is 
effective. 
 
Off-label prescribing is prevalent in many fields of medicine including: general medicine,2 
psychiatry,3 obstetrics,4 paediatrics,5-7 oncology,8-10 HIV/AIDS11 and palliative care.12,13  Off-label 
prescribing is best documented in paediatrics, with prevalence of 11% in general practice, 72% in a 
neonatal intensive care unit,5,14,15 and up to 89% of paediatric inpatients.16  In other populations, 
estimates of off-label prescribing vary: 8% in psychiatry inpatients,3 21% in office-based physicians,2 
40% in HIV patients,11 and up to 65% in oncology patients.10,17,18 
 
In palliative care, patients often have multiple pathologies and complex symptoms, are frequently on 
multiple medications19 and have fragile and rapidly changing health states.  Adequately designed 
clinical trials in this population are feasible but challenging. Consequently, many medications used in 
palliative care are prescribed off-label in a setting where drug-host and drug-drug interactions20 are 
already likely. Patients may also have limited ability to provide informed consent for off-label 
medications.21   
 
Pavis and Wilcock examined the off-label use of medications in palliative care in the United Kingdom 
in 2001 against General Medical Council (GMC) recommendations, finding low rates of verbal or 
written consent and poor documentation of reasons for off-label use in case notes.13 Whilst these 
GMC recommendations have since been updated,22 the questions asked remain by Pavis and 
Wilcock remain pertinent to quality prescribing.  The aim of this study was to examine off-label 
prescribing in Australian palliative medicine clinicians through a national point prevalence survey. 
 
 
 Methods 
1. Study setting 
Specialist palliative care services (SPCS) in Australia span a range of different service delivery models, 
from large regional multidisciplinary teams to single clinical nurses in small rural locations.  SPCS may 
include public and private hospitals with inpatient and/or consultative services, free-standing 
palliative care units, outpatient clinics and community care teams.  SPCS may be the primary health 
provider but more commonly work in consultation to support general practitioners, other specialists 
and community services.   
Study design and participants 
This cross-sectional study was part of a larger survey looking at prescribing practices.  The survey 
included: participants’ demographics, scopes of palliative medicine practice, level of experience, and 
perceptions and experience of off-label prescribing for the three medications in each respondent’s 
practice that he/she most often used off-label (Appendix 1). 
An invitation to participate, with a printed version of the survey, was sent in July 2010 to all 
Australian-based members of the Australia and New Zealand Society of Palliative Medicine 
(ANZSPM), a medical society open to doctors with an interest in palliative medicine.  The letter 
included a link to the online survey. 
Data collection 
Survey data were entered by participants using the online survey tool, or if completed on paper 
were entered by an administrative assistant.   
Data analysis 
Medication registration and listed indications were obtained from the Australian TGA website 
(www.tga.gov.au, accessed 9th August 2011).  All nominated medication/indication dyads, were 
classified as unregistered, off-label or on-label.  In Australia, whilst the TGA regulates medication 
approval, the Pharmaceutical Benefits Scheme (PBS) determines medication subsidy – ie. 
medications approved by the TGA do not automatically receive subsidy from the PBS, and if not, 
patients must pay full price.  Given this distinction and the potential to misconstrue on-label but 
unsubsidised dyads as off-label, on-label dyads were also grouped into subsidised and unsubsidised 
(www.pbs.gov.au, accessed 9th August 2011).  Uncertainty in interpretation of listed indications were 
reviewed by the authors and consensus reached.  As the TGA consider any medication registered for 
parenteral use can be given intravenously, intramuscularly, or subcutaneously if administerable 
without dilution, route of administration was not considered separately in the analysis.  Nominated 
indications by survey respondents were grouped for the purpose of analysis (e.g. nausea/vomiting, 
pain, delirium/agitation).   
Data were analysed using PWAS 18.0 (SPSS Corp. Inc., 2008. Chicago, IL. USA).  Descriptive statistics 
were used to analyse categorical variables, and comparisons using Chi-square test or Fisher’s exact 
test as appropriate.   
The reporting of this survey complies with the STROBE criteria for reporting cross-sectional studies.23  
Ethical approval for this study was granted by the Flinders University Social and Behavioural 
Research Ethics Committee.  
 
Results 
In July 2010, 213 of 220 registered ANZSPM members had a valid contact address and of these, 105 
(49%) provided valid responses for analysis.  Thirty-nine percent were male and >74% of the 
population were aged >40 years.  The majority had been practising medicine for more than ten years 
(91%), and Palliative Medicine for more than five years (78%).  Respondents worked in a variety of 
settings – acute inpatient (35%), hospital liaison (64%), community (46%), outpatient (46%) and 
palliative care unit (55%).  Most respondents (91%) saw >60 new patients per year. 
The majority of respondents reported that their services did not have, or were unaware of, a policy 
on providing information to patients about the off-label use of medications (89%), nor consistently 
limited the use of off-label use of medications to consultants (70%).  The documentation of consent, 
verbal or written, was variable but tended to be absent or inconsistent (Table 1). When asked to 
quantify the number of occasions verbal or written consent was obtained, or reasons documented in 
the notes, the number of occasions reported was frequently much lower than expected given the 
numbers of patients seen (Table 2).  For example, eight of the ten respondents who reported always 
documenting reasons for off-label prescribing saw >100 patients per year with life-limiting illnesses.  
However when asked to quantify consent and documentation, only seven gave a count of verbal or 
written consent, with six of the seven reporting ten or less occasions; furthermore the five 
respondents who gave a count of documenting in the notes all reported this ten or less times.  
Overall, 20% of respondents never obtained verbal nor written consent, nor documented a reason 
for off-label use. 
The 105 respondents proposed 236 off-label medication/indication dyads for 36 medications (Figure 
1, Table 3).  Forty-five (19%) dyads for two medications were unregistered (cyclizine and 
levomepromazine (methotrimeprazine) are not registered in Australia).  One hundred and eighteen 
(50%) dyads were off-label, covering 26 medications for 38 indications.  The remaining 73 (31%) 
dyads were on-label, covering 12 medications for 14 indications.  Of these 73 on-label dyads, 31 
were of pregabalin or gabapentin for pain, which are registered but not subsidised indications (off-
subsidy use). 
Discussion 
This study has found that palliative care practitioners have a poor understanding of medication 
regulations and the status of frequently used medications.  When asked about “licensed drugs for 
unlicensed uses”, only 50% of nominated medication/indication dyads were correct.   
Nineteen percent of the dyads were unregistered.  Previous registration for cyclizine and 
levomepromazine has expired, and given their limited general use and low commercial value, their 
sponsors have declined to update and renew their registration.  However, these medications are 
available in Australia using the Special Access Scheme, allowing importation of unregistered 
medications.  
The remaining 31% dyads were on-label.  Respondents may have mistaken on-label but unsubsidised 
medications with off-label use.  Furthermore, a number of nominated dyads may have been 
designated off-label because the route (eg. subcutaneous) was believed off-label.  This reflects poor 
understanding of medication regulation processes that lead to a medication being off-label.  
This poor understanding may be, in part, due to a widespread lack of service policies to guide off-
label prescribing.  Only 11% of respondents reported that their service had policies for the use of off-
label medications, however this was more than British palliative care services (2%) a decade ago13 
but less than American academic medical centres (17%)24 and Italian hospices (28%).25  The practices 
for off-label prescribing are reportedly better than for Pavis and Wilcock, with 26% of respondents in 
this study never seeking verbal consent (compared with 38%) and 76% never seeking written 
consent (compared with 93%), though never documenting reasons still occurred in approximately 
50% of cases.13  Whilst there may have been some improvement in practices around off-label 
prescribing since 2001, this survey demonstrates there are still large deficits though 100% 
compliance may not be necessary.22  Establishing a robust policy is a first step, but compliance with 
these policies is likely to be extremely limited given responses reflected into this survey.  
 
What are the issues around off-label prescribing? 
Clinically 
Off-label prescribing is not a new issue.26,27  Whilst some cases of off-label prescribing is clinically 
appropriate, studies have demonstrated that off-label prescribing: 
- is poorly recognised,28  
- may lack adequate informed consent processes,29,30  
- lacks the efficacy achieved in on-label prescribing,31,32 and  
- is more likely to be associated with increased or unrecognised adverse events.33-35   
And whilst off-label prescribing may have benefits, these must be weighed against harms to define 
the net clinical effect. 
 
Ethically 
The community reasonably expects that prescribing will be for indications approved by reputable 
regulatory authorities, supported by high quality evidence, and any deviation from this will be 
supported by robust policy and informed consent.36  Off-label medication use may blur the 
distinction between clinical practice and experimentation, creating significant ethical concerns.37  
Prescribers must understand the potential harms and benefits of a particular therapy (including 
uncertainties), any alternative therapeutic options and facilitate informed shared decision making 
with the patient.   
 
Legally 
Once a medication is registered, off-label use is a matter of medical judgement, shifting the focus of 
ethical and legal responsibility (and hence liability) from manufacturers/suppliers to the prescribing 
practitioner.1,38,39  Prescribing off-label is not prima facie evidence of medical negligence – 
negligence requires that the off-label use of the medication for the particular patient was not in line 
with a reasonable standard of medical care.40  Regulations prohibit the promotion of off-label uses of 
medications however historically there has been: omission or understating of risks, of overstating 
effectiveness, and of unjustifiable comparative claims for off-label medication use.41-43 
 
Why does off label prescribing exist? 
The TGA, EMEA and FDA regulate prescription medication marketing, not clinician nor institutional 
prescribing.28,43  Given the substantial resources required and evidence base needed to register a 
medication or update its indications there will always be off-label prescribing.44  In some cases this is 
supported by studies that underpin particular off-label indications, but regulatory approval has not 
been sought to cover the indication, dose or route of administration.29,45   
There are examples where off-label uses of medications have provided patients with improved 
outcomes, or where such prescribing genuinely reflects leading edge clinical care.46  Often this is 
where off-label prescribing was biologically plausible and supported by clinical evidence, although 
for yet unregistered indications.  Examples include imatinib for gastrointestinal stromal tumours,47 
morphine for dyspnoea,48 and immunomodulators in chronic autoimmune/inflammatory conditions.  
Expanding indications, or ‘indication creep’, may provide important therapeutic efficacy data, 
however measuring net clinical effect requires systematic assessment of benefits and harms.49,50  
The risk is that practitioners expand indications with limited scientific rationale while the 
pharmaceutical industry either passively observes broadening indications or actively promotes off-
label use even in the absence of evidence of efficacy and safety.50   
 
Prescribing is strongly influenced by local practice, anecdote or expert opinion, which may not 
always reflect best evidence.51,52  A study of American office-based physicians found that 73% of off-
label prescribing had little or no scientific support.2  Furthermore, as demonstrated in this study, 
many practitioners do not know whether or not they are working with registered indications, even in 
their area of specialty practice.28  
 
Off-label prescribing in palliative care? 
The available literature on off-label prescribing in palliative care suggests that 12-26% of 
prescriptions are off-label,12,25,53 with low rates of system-level strategies to address off-label 
prescribing.25  Off-label prescribing may be biologically plausible, as with octreotide for malignant 
bowel obstruction, or supported by high-level evidence, as in the case of morphine for dyspnoea.   
 
A number of factors have hindered the building of an evidence base for prescribing in palliative care.  
This population is often considered difficult to study, due to declining and unstable health, 
comorbidities, cognitive dysfunction, and ‘gate-keeping’ to ‘protect’ patients from clinical trials 
perceived too burdensome despite patient and caregiver support. 54-56  Many of the medications 
commonly used in palliative care are off patent, and thus there is little incentive for further research 
or to expand registration when definitive studies emerge.  
 
Limitations 
This study relies on self-report with no easy way to provide third party verification of the data 
presented.  Furthermore, given the demonstrated poor understanding of off-label prescribing, 
respondents’ self-report may not reflect the extent of their off-label prescribing and likely to 
underestimate the prevalence.  Furthermore the sample may be biased, with respondents 
potentially those most conscious of issues surrounding off-label use and therefore the estimates are 
a more positive picture than the day-to-day reality.  Without accurate quantification of the 
prevalence of off-label prescribing, the interpretation of these data is limited.  
 
Implications for practice 
Ethical off-label use requires at least one of the following:  
- existing high-level evidence;  
- in the setting of a properly designed rigorous clinical trial; or 
- exceptional use justified by individual clinical circumstances.29   
To evaluate the appropriateness of off-label medication use, proposed frameworks consider the 
level of evidence available and give guidance as to the level of consent, pharmacovigilance, and 
ongoing review required (Figure 2).22,29,37,57  As with any treatment decision, but especially pertinent 
in cases with low certainty of net clinical effect, a process of shared decision making with the patient 
is required.  This should include disclosure of the nature of off-label use, the benefits and harms, the 
evidence to support the off-label use, and why in the particular patient’s circumstances, the 
prescriber believes there is no equivalent or better TGA/EMEA approved alternative.36,57  This should 
be supported by documentation of the informed consent process and discussion in the medical 
notes.57,58 
 
Given the uncertainties of benefits or harms, there is a need to specify treatment goals and to 
monitor net clinical effect at intervals determined by expected time to response, and requirements 
for medication titration.44,59,60  Ideally formal review of efficacy, safety and cost outcomes should 
occur to guide further practice.37 As a minimum, prospective data should be collected on the net 
clinical effects of the off-label use of medications, and such data aggregated.61 
Whilst changing clinician behaviour can be difficult,51 provision of valid evidence and interventions 
targeting prescribing have been shown to change clinician understanding and prescribing 
behaviour.50,62  Other potential strategies include requiring the primary indication when prescribing, 
which would facilitate post-marketing surveillance.63  Reducing administrative and financial barriers 
to approving new indications for registered medications would remove key obstacles to updating 
registration without lessening the level of evidence required.  Professional and regulatory bodies can 
also guide health policy and influence clinician prescribing.57  The role of the pharmaceutical industry 
in promoting off-label prescribing has become more widely recognised in recent cases such as 
gabapentin,64 oxycodone65 and erythropoietin,66 and substantial penalties have been imposed in an 
attempt to discourage such actions.67 
 
Implications for research 
A lack of evidence of effect does not equate to evidence of ineffectiveness.  There needs to be 
prioritisation of research to improve the evidence for medications used off-label in palliative care, 
particularly those: used frequently, with high cost, with significant potential benefits and/or harms, 
or with little supporting evidence.68,69  Accurate, prospective determination of the prevalence of off-
label prescribing in palliative care, and the medications used, will help guide studies to improve the 
evidence base.   
With regular monitoring of prescribing practice, emerging medication/indication dyads can be 
identified and appropriate studies performed to build an evidence base.  At a minimum, 
pharmacokinetic studies could be performed in healthy volunteers, but ideally comparative 
effectiveness studies to identify efficacy compared to non-pharmacological and on-label options, but 
also systematically address iatrogenic harm, toxicity and cost-effectiveness, giving an indication of 
net clinical effect.  Should a medication/indication dyad prove beneficial, the dyad should be 
submitted to the regulatory bodies for registration.  Ongoing post-registration evaluation of benefits 
and harms is required to ensure that the medication is performing as expected. 
Further work is required on strategies to optimise prescribing practices, and to develop policies 
around off-label use of medications. 
Conclusion 
Off-label prescribing in Australian palliative medicine clinicians is poorly recognised and has clinical, 
legal and ethical implications for the management of palliative care patients. 
Two key questions need to be asked in considering off-label use of medications: 
- Does quality evidence exist but registration has not been updated by the pharmaceutical 
sponsors?; and  
- Has the evidence not been generated (or exists and suggests that there is no net clinical 
benefit)?   
 
For clinicians, categorising the medication under one of these two scenarios will guide 
appropriateness and level of consent, and this should be complemented with subsequent 
pharmacovigilance for net clinical effect.  For policy makers and funding bodies, medications used 
off-label where there is insufficient evidence should be targeted for further research with a view to 
updating registration if subsequent studies demonstrate net clinical benefit. More research is 
required to determine the prevalence and clinical consequences of off-label prescribing in palliative 
care and to direct intervention for clinicians and patients. 
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Appendix 1. Survey of the use of licensed drugs for un-licensed uses in palliative care.  
 
  
Table 1. Respondents’ practices regarding off-label prescribing and associated verbal or written 
consent, and documentation of reasons. 
 Always (%) Sometimes (%) Never (%) 
Do you limit off-label 
prescribing to 
consultants only? 
29 (29) 39 (39) 31 (31) 
Do you obtain verbal 
consent from the 
patient/caregiver? 
24 (24) 49 (50) 26 (26) 
Do you obtain written 
consent from the 
patient/caregiver? 
1 (1) 23 (24) 74 (76) 
Do you document in 
your notes when 
prescribing off-label & 
the reasons for this? 
10 (10) 38 (39) 49 (51) 
 
Table 2. Number of occasions of verbal or written informed consent, and documentation of the 
reason in the notes for off-label prescribing in the last six months. 
 
Number of occasions Verbal or written consent† 
n=67 
Documentation in notes‡ 
n=54 
0 18 (27%) 23 (43%) 
1-5 17 (25%) 18 (33%) 
6-10 17 (25%) 10 (19%) 
>10 15 (22%) 3 (6%) 
 
†38/105 (36%) had no response 
‡51/105 (49%) had no response
Table 3. Top nominated medication/indication dyads categorised by unregistered medication, off-label use, and on-label use. 
 
Unregistered Indication n Off-label Indication n On-label Indication n 
Levomepromazine Nausea/vomiting 19 Ketamine Pain 24 Haloperidol Nausea/vomiting 22 
 Delirium/agitation 2 Octreotide Malignant bowel 
obstruction 
20 Gabapentin Pain 19 
 Sedation 1  Nausea/vomiting 2 Pregabalin Pain 12 
 Dyspnoea 1 Clonazepam Delirium/agitation 7 Midazolam Sedation 4 
 Blank 1  Sedation 6  Agitation 2 
Cyclizine Nausea/vomiting 19  Anxiety 3 Metoclopramide Nausea/vomiting 5 
 Malignant bowel 
obstruction 
1  Pain 2    
 Blank 1  Distress 1    
   Olanzapine Delirium/agitation 5    
    Nausea/vomiting 3    
   Midazolam Anxiety 4    
    Dyspnoea 2    
    Pain 1    
   Morphine Dyspnoea 6    
 
 
 
 
Figure 1. Nominated medication/indication dyads categorised by unregistered, off-label and on-label 
(n=236). 
 
Figure 2. Assessing appropriateness of off-label medicines use29 
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